2 weeks Ago By Defense World Staff
Puma Biotechnology, Inc. ( NASDAQ:PBYI – Free Report ) – Equities researchers at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for Puma Biotechnology in a research note issued on Thursday, September 26th. Zacks Research analyst R.
Department now anticipates that the biopharmaceutical company will post earnings of $0.19 per share for the year, down from their prior estimate of $0.22.
The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share. PBYI has been the topic of a number of other reports.
StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $7.
00 price target on shares of Puma Biotechnology in a report on Friday, August 2nd. Puma Biotechnology Price Performance PBYI opened at $2.58 on Monday.
The company has a debt-to-equity ratio of 0.90, a current ratio of 1.32 and a quick ratio of 1.
23. The stock has a market capitalization of $126.55 million, a P/E ratio of 7.
82 and a beta of 1.09. The company’s 50 day simple moving average is $2.
93 and its 200-day simple moving average is $3.82. Puma Biotechnology has a one year low of $2.
13 and a one year high of $7.73. Puma Biotechnology ( NASDAQ:PBYI – Get Free Report ) last issued its quarterly earnings results on Thursday, August 1st.
The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.
01. The business had revenue of $47.10 million for the quarter, compared to the consensus estimate of $43.
99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.
36%. During the same quarter in the prior year, the company earned $0.05 EPS.
Institutional Trading of Puma Biotechnology A number of hedge funds have recently modified their holdings of the company. Great Point Partners LLC acquired a new stake in Puma Biotechnology in the fourth quarter worth $4,734,000. Affinity Asset Advisors LLC acquired a new stake in Puma Biotechnology during the 2nd quarter worth $815,000.
SG Americas Securities LLC acquired a new stake in Puma Biotechnology during the 1st quarter worth $57,000. O Shaughnessy Asset Management LLC lifted its holdings in Puma Biotechnology by 127.7% during the first quarter.
O Shaughnessy Asset Management LLC now owns 77,081 shares of the biopharmaceutical company’s stock worth $409,000 after acquiring an additional 43,229 shares in the last quarter. Finally, Assenagon Asset Management S.A.
grew its stake in Puma Biotechnology by 99.9% in the second quarter. Assenagon Asset Management S.
A. now owns 140,205 shares of the biopharmaceutical company’s stock valued at $457,000 after acquiring an additional 70,060 shares during the period. 61.
29% of the stock is currently owned by institutional investors and hedge funds. Insider Activity at Puma Biotechnology In other Puma Biotechnology news, CEO Alan H. Auerbach sold 21,920 shares of Puma Biotechnology stock in a transaction on Wednesday, July 17th.
The shares were sold at an average price of $3.70, for a total transaction of $81,104.00.
Following the completion of the sale, the chief executive officer now owns 7,063,515 shares of the company’s stock, valued at approximately $26,135,005.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink .
In other Puma Biotechnology news, CEO Alan H. Auerbach sold 18,885 shares of the stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $3.
27, for a total value of $61,753.95. Following the transaction, the chief executive officer now owns 7,085,435 shares of the company’s stock, valued at $23,169,372.
45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link . Also, CEO Alan H.
Auerbach sold 21,920 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total value of $81,104.
00. Following the transaction, the chief executive officer now owns 7,063,515 shares in the company, valued at approximately $26,135,005.50.
The disclosure for this sale can be found here . Insiders have sold 82,263 shares of company stock worth $286,469 over the last ninety days. Company insiders own 23.
70% of the company’s stock. About Puma Biotechnology ( Get Free Report ) Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
See Also Five stocks we like better than Puma Biotechnology What is the S&P/TSX Index? Simon Property REIT: A Safe Bet for Growth and Steady Dividends What is the Nikkei 225 index? CarMax’s Impressive Rally: What Investors Should Watch Next Insider Trades May Not Tell You What You Think MarketBeat Week in Review – 9/23 – 9/27 Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter ..
